《Bulletin Du Cancer》是一本以French為主的未開放獲取國(guó)際優(yōu)秀期刊,中文名稱癌癥公告,本刊主要出版、報(bào)道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果,介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展,探討行業(yè)發(fā)展的思路和方法,以促進(jìn)學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用,也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為1.1,最新CiteScore 指數(shù)為1.9。
本刊近期中國(guó)學(xué)者發(fā)表的論文主要有:
Therapeutic effect of haploidentical peripheral blood stem cell treatment on relapsed/refractory ovarian cancer
PTBP1 promotes tumorigenesis by regulating apoptosis and cell cycle in colon cancer
Author: Xiaona Li, Fei Han, Wenbin Liu, Xiaoyan Shi
英文介紹
Bulletin Du Cancer雜志英文介紹
Without doubt, the 'Bulletin du Cancer' is the French language publication of reference in the field of cancerology. Official organ of the French Society of Cancer, this journal covers all the information available, whether in the form of original articles or review articles, but also clinical cases and letters to the editor, including various disciplines as onco-hematology, solids tumors, medical oncology, pharmacology, epidemiology, biology as well as fundamental research in cancerology. The journal proposes a clinical and therapeutic approach of high scientific standard and regular updates in knowledge are thus made possible. Articles can be submitted in French or English.